Announcements

AmMetLife and Heydoc Health Launch Malaysia’s First Data-Driven Drug Optimisation Program to Enhance Affordability in Healthcare Coverage

25 August 2025

(Left to Right) Leong Chee Wan, Head of Operations, AmMetLife; Rangam Bir, CEO, AmMetLife; Dr. Raymond Choy, Chief Executive Officer. Heydoc Health; Fabian Lim, Chief Commercial Officer,Heydoc Health

 

AmMetLife Insurance Berhad (AmMetLife) has signed a Memorandum of Understanding (MoU) with Heydoc Health to launch Malaysia’s first drug optimisation program, leveraging data-driven insights and technology to improve the affordability and long-term sustainability of healthcare coverage. The strategic collaboration aims to help customers access the right medication at fair prices, without comprising quality or continuity of care.

Under this MoU, Heydoc Health’s platform will analyse publicly available pricing data for commonly prescribed medications to benchmark real-world market prices, providing pricing recommendations that are affordable for patients while sustainable for providers, and updating these dynamically as market conditions change. AmMetLife will use these pricing benchmarks to ensure its network hospitals and clinics maintain competitive charges, giving customers the best value in medical care.

Rangam Bir, Chief Executive Officer of AmMetLife, said: "The escalating cost of healthcare is a challenge that can no longer be addressed by traditional methods alone. At AmMetLife, we are committed to forward-thinking partnerships that protect our customers today and future-proof our health and medical insurance solutions. Working with Heydoc Health allows us to leverage technology to ensure affordability without compromising care."

Dr. Raymond Choy, Chief Executive Officer of Heydoc Health, said: "We are excited to partner with AmMetLife on this initiative, which marks a major step toward achieving fairer, smarter healthcare financing in Malaysia. By applying data analytics, we can deliver value-based care and patients benefit from improved access to affordable, high-quality treatment.”

The program will roll out in phases, starting with high-utilisation medications and expanding to a wider range over time, delivering consistent savings and supporting the long-term sustainability of healthcare coverage for Malaysians.

cta background